A Multicentre, Open-label, Randomised Phase IV Study to Investigate Acalabrutinib Monotherapy Compared to Investigator's Choice of Treatment in Adults (> 18 Years) With Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment
Latest Information Update: 28 Jun 2025
At a glance
- Drugs Acalabrutinib (Primary)
- Indications Cardiovascular disorders; Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors AstraZeneca
Most Recent Events
- 24 Mar 2025 Planned End Date changed from 29 Jan 2031 to 16 Aug 2030.
- 24 Feb 2025 Planned End Date changed from 25 Dec 2030 to 29 Jan 2031.
- 24 Feb 2025 Status changed from not yet recruiting to recruiting.